A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.

Aronne, L J

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. [electronic resource] - International journal of obesity (2005) May 2010 - 919-35 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial

1476-5497

10.1038/ijo.2010.21 doi


Adult
Aged
Aged, 80 and over
Amides--administration & dosage
Anti-Obesity Agents--administration & dosage
Body Mass Index
Body Weight--drug effects
Diet, Reducing
Double-Blind Method
Female
Humans
Male
Metabolic Syndrome--drug therapy
Middle Aged
Obesity--drug therapy
Pyridines--administration & dosage
Receptor, Cannabinoid, CB1--agonists
Risk Assessment
Treatment Outcome
Young Adult